Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EXCL-100
- Development stage
- Unknown
- Lead developer
- Excalibur Pharmaceuticals
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral
01
Overview
EXCL-100 is a sustained-release oral tablet formulation of pirfenidone developed by Excalibur Pharmaceuticals. Pirfenidone is an antifibrotic agent primarily indicated for the treatment of idiopathic pulmonary fibrosis (IPF). The mechanism of action involves inhibition of transforming growth factor-beta (TGF-β)–stimulated collagen synthesis, decreasing the production of fibrogenic mediators and reducing fibroblast proliferation. EXCL-100 was evaluated in a Phase 1 clinical trial comparing its pharmacokinetics and bioavailability to Esbriet (pirfenidone) in healthy volunteers[1].
- Other names
- EXCL-100EXCL100EXCL 100600 MG Oral Tablet
Beyond the preview
Go deeper on EXCL-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EXCL-100.